Institutional Investors Reduce Stake Below 5% in Bolt Biotherapeutics
Summary
A group of institutional investors, including Nan Fung Group and Pivotal bioVenture Partners, reported selling approximately $194,521 worth of shares, reducing their collective beneficial ownership in Bolt Biotherapeutics below the 5% threshold.
Key Events
-
Institutional Stake Reduced
A group of institutional investors, including Nan Fung Group and Pivotal bioVenture Partners, reported that their collective beneficial ownership in Bolt Biotherapeutics, Inc. has fallen below the 5% threshold as of February 26, 2026.
-
Significant Share Sales
The reporting persons sold a total of 40,669 shares between February 17, 2026, and February 26, 2026, for a total transaction value of approximately $194,521.
-
Ongoing Reduction
This filing follows a previous Schedule 13D/A on February 18, 2026, indicating a continued reduction in their holdings over the past week.
Analysis
A group of institutional investors, including Nan Fung Group and Pivotal bioVenture Partners, has significantly reduced its stake in Bolt Biotherapeutics, falling below the 5% beneficial ownership threshold. This action, involving the sale of over $194,000 worth of shares, signals a notable decrease in conviction or a strategic reallocation of capital by these major holders. For a micro-cap company, such a reduction by a significant institutional investor can be interpreted negatively by the market, potentially impacting investor sentiment and liquidity.
At the time of this filing, BOLT was trading at $4.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $4.27 to $9.66. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.